

Lung cancer: diagnosis and management (update)

NICE guideline: acknowledgments

NICE guideline xxxx

Authors and contributors

September 2018

Draft for Consultation

*Commissioned by the National Institute for
Health and Care Excellence*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE [2018]. All rights reserved. Subject to [Notice of rights](#).

Contents

1	Review Questions.....	5
----------	------------------------------	----------

1 Review Questions

RQ No.	Review Question
1.1	What is the clinical and cost effectiveness of using non-ultrasound-guided TBNA, EBUS-TBNA or EUS-FNA as the first test for people with an intermediate probability of mediastinal malignancy?
1.2	What is the clinical and cost-effectiveness of EBUS-TBNA alone, EUS-FNA alone or EBUS-TBNA and EUS-FNA in combination compared with surgical staging to diagnose and/or stage lung cancer?
1.3	What is the clinical and cost-effectiveness of routine imaging of the head in the management of people with lung cancer before radical therapy with curative intent?
3.1	What is the clinical and cost effectiveness of chemotherapy, radiotherapy or surgery (alone or in combination) for the treatment for N2 stage NSCLC?
3.2	What is the clinical and cost effectiveness of different radiotherapy regimens with curative intent for NSCLC (stage T1a–2b N0 M0)?
3.3	What is the clinical and cost effectiveness of the following systemic anti-cancer therapy regimens for treating NSCLC: <ul style="list-style-type: none"> • platinum combinations compared with non-platinum combinations in people with advanced NSCLC (stage III or IV) • non-platinum monotherapy compared with non-platinum combinations in people with advanced NSCLC (stage III or IV) who cannot tolerate platinum combinations
3.4	What is the most clinically and cost-effective regimen of chemoradiotherapy for people with limited-stage SCLC?
3.5	In people with extensive-stage SCLC who have had first-line treatment with systemic anti-cancer therapies, when is first use of thoracic radiotherapy clinically and cost effective?
4.1	What is the clinical and cost effectiveness of cranial irradiation for brain metastases in people with NSCLC?
4.2	What is the clinical and cost-effectiveness of prophylactic cranial irradiation to prevent brain metastases in people with SCLC?